Health and Fitness Health and Fitness
Tue, January 13, 2009
[ 04:00 AM ] - Market Wire
DexCom" Amends Joint Development Agreement with A .. cose Monitoring-Enabled Insulin Pumps Outside U.S
[ 04:00 AM ] - Market Wire
Celldex Announces Sale of Poultry Vaccines Business to Lohmann
[ 04:00 AM ] - Market Wire
NMT Medical Provides Preliminary Year End Financial Results and Clinical Trial Update
[ 04:00 AM ] - Market Wire
Emeritus Announces Preliminary Fourth Quarter Occupancy Information
[ 04:00 AM ] - Market Wire
Incyte to Announce 2009 Objectives at JPMorgan He .. onference; JAK Inhibitor Program Highest Priority
[ 03:30 AM ] - Market Wire
Invitrogen Receives Approval from Health Canada f .. to Help Determine Organ Transplant Compatibility
[ 03:30 AM ] - Market Wire
ProUroCare Medical Inc. Announces Closing of Public Equity Offering
[ 03:30 AM ] - Market Wire
ARIAD Announces 2009 Key Corporate Objectives
[ 03:00 AM ] - Market Wire
Genzyme Biosurgery Shareholders Receive $64 Milli .. ettlement in Victory over the Genzyme Corporation
[ 02:05 AM ] - Market Wire
Health Management Associates, Inc. Previews Fourt .. ar-End 2008 Results and Announces 2009 Objectives
[ 02:00 AM ] - Market Wire
Zacks Bull & Bear of the Day Highlights: Baxter I .. Energy, D.R. Horton, The Gap and Harley-Davidson
[ 02:00 AM ] - Market Wire
Illumina Announces High Density Expansion to iSelect® Custom Genotyping Platform
[ 12:00 AM ] - Market Wire
Santarus Announces Complete Response Letter from .. ing-Plough?s New Drug Application for OTC ZEGERID
Mon, January 12, 2009
[ 08:55 PM ] - Market Wire
Elan Clarifies Duration of Bapineuzumab Phase 3 Trials
[ 07:34 PM ] - Market Wire
The Medicines Company: The Medicines Company to Acquire Targanta Therapeutics
[ 03:09 PM ] - Market Wire
Resumen: ReGen Biologics presentar el implante de .. M en la reunin de la Academia Americana de ciruja
[ 03:08 PM ] - Market Wire
Samenvatting: ReGen Biologics introduceert de Men .. nt bij de American Academy of Orthopaedic Surgeon
[ 02:35 PM ] - Market Wire
Prestige Brands Holdings, Inc. Projects Fiscal 2009 Third Quarter Revenues in Line with Prior Year
[ 02:10 PM ] - Market Wire
AVI BioPharma, Inc.: AVI BioPharma and Collaborat .. tiveness of PPMO-Based Splice Switching Oligomers
[ 01:54 PM ] - Market Wire
Orthofix International Files Definitive Proxy Statement
[ 01:30 PM ] - Market Wire
Wellstar International, Inc.: Wellstar/TMI Joins Fight Against Bedsores Epidemic
[ 01:00 PM ] - Market Wire
King Pharmaceuticals to Present at JPMorgan Healthcare Conference
[ 12:05 PM ] - Market Wire
EXACT Sciences Board of Directors Rejects Acquisition Proposal from Sequenom, Inc.
[ 12:05 PM ] - Market Wire
AngioDynamics Acquires FlowMedica Benephit® Renal Therapy Product Line
[ 12:00 PM ] - Market Wire
Bristol-Myers Squibb and ZymoGenetics Enter Global Collaboration on Novel Hepatitis C Compound
[ 12:00 PM ] - Market Wire
Adolor Corporation to Present at 27th Annual J. P. Morgan Healthcare Conference
[ 12:00 PM ] - Market Wire
Centene Corporation Names John T. Severine as Vice President of Real Estate
[ 11:11 AM ] - Market Wire
Richmond Minerals Inc.: Richmond Minerals Inc. Announces Private Placement
[ 11:00 AM ] - Market Wire
NitroMed Receives Revised Unsolicited Acquisition Proposal from Deerfield Management
[ 10:17 AM ] - Market Wire
Schaeffer's Street Stories: After an Upgrade, Pfizer Inc. is Little Changed

Schaeffer's Street Stories: After an Upgrade, Pfizer Inc. is Little Changed


Published on 2009-01-12 11:36:58, Last Modified on 2009-01-12 11:37:17 - Market Wire
  Print publication without navigation


CINCINNATI--([ BUSINESS WIRE ])--Some bullish news hit the Street today for blue chip pharmaceutical concern Pfizer Inc. (NYSE: PFE). Goldman Sachs removed PFE from its Americas Sell List. The brokerage firm said, "Pressure is mounting on management to do something big and soon."

"Almost regardless of what precisely this action is, we believe the stock would respond positively to a sign of positive, dramatic change at Pfizer," Goldman analyst Jami Rubin said in a note to investors. The firm upgraded the stock from "sell" to "neutral."

To continue reading this article, click here: [ http://www.schaeffersresearch.com/commentary/content/after+an+upgrade+pfizer+inc+is+little+changed/observations.aspx?click=home&ID=90439 ]

Contributing Sources